TELA Bio, Inc.: approves potential reverse stock split amendment

What happened

• TELA Bio, Inc. reported that at a Special Meeting of Stockholders held virtually on Oct 8, 2026 stockholders approved an amendment to the Company’s Certificate of Incorporation to combine outstanding shares of common stock by a ratio of not less than 1-for-5 and not more than 1-for-15, with the exact ratio to be set by the board in its sole discretion.
• The filing reports that the company does not intend to effect the reverse stock split at this time after receiving a letter from The Nasdaq Stock Market LLC on Oct 5, 2026 stating the company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market.

Key details

• Record date: Sep 8, 2026; outstanding shares as of the record date: 45,143,410.
• Proposal 1 (approve amendment to combine shares) vote: For 30,515,571; Against 80,512; Abstentions 1,737,011; Broker non-votes 0.
• Proposal 2 (adjournment, if necessary) vote: For 30,757,679; Against 123,860; Abstentions 1,451,555; Broker non-votes 0.
• The Special Meeting was conducted virtually. The company previously reported receipt of Nasdaq’s Oct 5, 2026 letter that it has regained compliance with Nasdaq Listing Rule 5450(a)(1).

Why it may matter

• This Form 8-K reports Item 5.07: submission of matters to a vote of security holders, covering approval of an amendment to the Certificate of Incorporation to permit a reverse stock split within a 1-for-5 to 1-for-15 range and approval of an adjournment proposal.
• The filing does not show why the insider traded or why the company acted.